MYC (8q24) Orange + Copy Control 8 Green

Product Description

The MYC gene belongs to a family of transcription factors that under normal conditions it controls cell cycle progression (1). However, in multiple types of cancer, MYC is considered a Proto-oncogene (1). MYC gene deregulation is identified in multiple malignancies such as Burkitt’s lymphoma, diffuse large B-cell lymphoma, and B-cell lymphoma (2). MYC gene amplifications, rearrangements, and/or point mutations are considered the underlying mechanisms that induce MYC gene deregulation (1). Specifically, a MYC gene rearrangement is considered a prognostic marker in several cancer subtypes. MYC gene rearrangements can be identified using conventional cytogenetic techniques such as fluorescence in situ hybridization (FISH).

Specifications

1. Aquino, Gabriella, Laura Marra, Monica Cantile, Annarosaria De Chiara, Giuseppina Liguori, Maria Curcio, Rocco Sabatino, Giuseppe Pannone, Antonio Pinto, Gerardo Botti, and Renato Franco. “MYC Chromosomal Aberration in Differential Diagnosis between Burkitt and Other Aggressive Lymphomas.” Infectious Agents and Cancer (2013): 1-9. Print.
2. Munoz-Marmol, Ana M, Carolina Sanz, Gustavo Tapia, Ruth Marginet, Aurelio Ariza, and Jose L Mate. “MYC Status Determination in Aggressive B-cell Lymphoma the Impact of FISH Probe Selection.” Histopathology
(2013): 418-24. Print.
3. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.